(S)-(+)-dimethyl (3-methyl-2-oxo-4-phenylbutyl)phosphonate | 123586-93-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-(+)-dimethyl (3-methyl-2-oxo-4-phenylbutyl)phosphonate
• 英文别名: (3S)-1-dimethoxyphosphoryl-3-methyl-4-phenylbutan-2-one
• CAS: 123586-93-6
• 化学式: C₁₃H₁₉O₄P
• 分子量: 270.265
• InChiKey: LBWWUETVPADDAK-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (S)-(+)-dimethyl (3-methyl-2-oxo-6-phenylhexyl)phosphonate 、 溴甲苯 在 (S)-(+)-dimethyl (3-methyl-2-oxo-4-phenylbutyl)phosphonate 、 crude product 、 silica gel 、 ethyl acetate heptane 作用下， 以afforded the title compound (680 mg) as a colorless oil的产率得到(S)-(+)-dimethyl (3-methyl-2-oxo-4-phenylbutyl)phosphonate
  参考文献：
  名称：

  DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS

  摘要：

  本文披露了使用式(I)化合物或包含式(I)化合物和药物可接受载体的组合物治疗骨质疏松症、骨折、骨质流失和增加骨密度的方法和组合物。其中，L1、L2、L4、R1、R4、R5、R6和s如规范中所定义。

  公开号：

  US20150174099A1
• 作为试剂：
  描述：

  (S)-(+)-dimethyl (3-methyl-2-oxo-6-phenylhexyl)phosphonate 、 溴甲苯 在 (S)-(+)-dimethyl (3-methyl-2-oxo-4-phenylbutyl)phosphonate 、 crude product 、 silica gel 、 ethyl acetate heptane 作用下， 以afforded the title compound (680 mg) as a colorless oil的产率得到(S)-(+)-dimethyl (3-methyl-2-oxo-4-phenylbutyl)phosphonate
  参考文献：
  名称：

  DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

  摘要：

  本文公开了式（I）化合物及使用式（I）化合物的治疗方法，其中L1、L2、L4、R1、R4、R5、R6和s的定义如规范中所述。式（I）化合物是EP4激动剂，可用于治疗青光眼、神经病性疼痛和相关疾病。

  公开号：

  US20160024006A1

文献信息

• [EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015246A1

  公开（公告）日：2014-01-23

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  披露的是通过给予公式(I)化合物的组合物和方法来治疗骨质疏松症、骨折、骨丢失以及增加骨密度，其中组合物包含公式(I)的化合物和药用可接受的载体，其中L1、L2、L4、R1、R4、R5、R6和s按说明书定义。
• METABOLICALLY STABLE PUROMYCIN ANALOGS
  申请人：Gumina Guiseppe

  公开号：US20090069556A1

  公开（公告）日：2009-03-12

  Disclosed are structurally modified, metabolically stable nucleosides having antitumor activity wherein the formation of toxic metabolites is blocked and antimicrobial activity. The disclosure further relates to pharmaceutical compositions comprising one or more disclosed modified nucleosides and to methods of use thereof.

  揭示了具有抗肿瘤活性的结构修饰、代谢稳定的核苷，其中阻止了有毒代谢物的形成和抗微生物活性。该公开还涉及包含一个或多个上述修饰核苷的药物组合物以及其使用方法。
• Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
  申请人：Cayman Chemical Company, Inc.

  公开号：US09440919B2

  公开（公告）日：2016-09-13

  Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  本文披露了通过给予式(I)化合物或含有式(I)化合物和药用可接受载体的组合物来治疗骨质疏松症、骨折、骨质丢失和增加骨密度的组合物和方法，其中L1、L2、L4、R1、R4、R5、R6和s如规范中所定义。
• METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH
  申请人：CAYMAN CHEMICAL COMPANY, INC.

  公开号：US20160158413A1

  公开（公告）日：2016-06-09

  The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

  本发明涉及一种新型骨组成物，用于局部向骨缺损部位提供治疗剂。治疗剂可以促进骨缺损的修复和/或治疗疼痛、炎症、癌症和感染等病症或疾病。该组成物包括磷酸钙水泥和脱矿骨基质或胶原海绵。该组成物可用于患者的骨缺损部位植入。
• Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
  申请人：Cayman Chemical Company, Inc.

  公开号：US10556862B2

  公开（公告）日：2020-02-11

  Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

  此处公开的是式 (I) 化合物 以及用式（I）化合物进行治疗的方法，其中 L1、L2、L4、R1、R4、R5、R6 和 s 如说明书中所定义。式（I）化合物是 EP4 激动剂，可用于治疗青光眼、神经性疼痛及相关疾病。